EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A high-throughput assay platform to discover small molecule activators of the phospholipase PLC-γ2 to treat Alzheimer's disease

Adam J Carr, Nicole Hajicek, Andy P Tsai, Padam P Acharya, P Brian Hardy, Emma Meyer, Tony Wyss-Coray, Kenneth H Pearce, John Sondek, Qisheng Zhang

Journal of Biological Chemistry · 2025-04 · 301 (4) · 108356

DOI: 10.1016/j.jbc.2025.108356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025-04. Verfasst von Adam J Carr und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Ca…. Hauptthemen laut MEDLINE: Alzheimer Disease, Phospholipase C gamma, High-Throughput Screening Assays, Small Molecule Libraries. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A naturally occurring missense variant of the phospholipase C isozyme, PLC-γ2, harboring a single substitution (P522R) protects against several neurodegenerative diseases, including Alzheimer's disease. The phospholipase activity of PLC-γ2 (P522R) is slightly elevated relative to its WT counterpart, and the general consensus is that this increased activity in microglia confers protection against neurodegeneration. In order to phenocopy this protection, we have developed a high-throughput assay to identify small molecule activators of PLC-γ2. The assay takes advantage of the fluorescent reporter, XY-69, embedded in lipid vesicles to readout the allosteric activation of PLC-γ2. The assay is highly reproducible and capable of identifying compounds with a large range of efficacies. A series of secondary assays have been established to define the selectivity of compounds for PLC-γ2, establish relevant activation of PLC-γ2 by compounds in a microglia cell line, and measure affinities between PLC-γ2 and hit compounds. The established workflow was prototyped using approximately 6000 compounds to produce several promising hits, but more importantly, enables screens of much larger chemical libraries to identify selective activators of PLC-γ2 to be used as chemical probes and drug leads.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseasePhospholipase C gammaHigh-Throughput Screening AssaysSmall Molecule LibrariesEnzyme ActivatorsHumansMicrogliaAnimalsCell LineEnzyme Activation

Stichwörter der Autor:innen

Alzheimer's diseaseallosteric regulationhigh-throughput screeninglipid metabolismmicrogliaphagocytosisphospholipase Csmall molecule activators

Substanzen

Phospholipase C gammaSmall Molecule LibrariesEnzyme Activators

Autor:innen und Institutionen

  • Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Wu Tsai Neurosciences Institute, Stanford University, Stanford, California, USA; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
  • Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Center for Integrative Chemical Biology and Drug Discover…
  • Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel…

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • NIA NIH HHS
  • Larry L. Hillblom Foundation
  • National Institutes of Health
  • University of North Carolina
  • Eisai Incorporated
  • Cure Alzheimer's Fund

Zitieren

APA

Carr, A. J., Hajicek, N., Tsai, A. P., Acharya, P. P., Hardy, P. B., Meyer, E., Wyss-Coray, T., Pearce, K. H., Sondek, J., & Zhang, Q. (2025). A high-throughput assay platform to discover small molecule activators of the phospholipase PLC-γ2 to treat Alzheimer's disease. Journal of Biological Chemistry, 301(4), 108356. https://doi.org/10.1016/j.jbc.2025.108356

Vancouver

Carr AJ, Hajicek N, Tsai AP, Acharya PP, Hardy PB, Meyer E, et al. A high-throughput assay platform to discover small molecule activators of the phospholipase PLC-γ2 to treat Alzheimer's disease. Journal of Biological Chemistry. 2025;301(4):108356. doi:10.1016/j.jbc.2025.108356

BibTeX
@article{Carr2025,
  author = {Carr, Adam J and Hajicek, Nicole and Tsai, Andy P and Acharya, Padam P and Hardy, P Brian and Meyer, Emma and Wyss-Coray, Tony and Pearce, Kenneth H and Sondek, John and Zhang, Qisheng},
  title = {A high-throughput assay platform to discover small molecule activators of the phospholipase PLC-γ2 to treat Alzheimer's disease},
  journal = {Journal of Biological Chemistry},
  year = {2025},
  volume = {301},
  number = {4},
  pages = {108356},
  doi = {10.1016/j.jbc.2025.108356}
}
Kostenlos starten →